Methods: This trial was a randomized phase II trial to evaluate modified (m)-FOLFOXIRI (irinotecan 150mg/m 2, oxaliplatin 85mg/m 2, 5-FU 2400mg/m2 ) plus cet ...
確定! 回上一頁